Neuromodulation Market by Technology (Internal, External), Stimulation Type (Spinal Cord, Deep Brain, Vagus Nerve Stimulation), Application (Ischemia, Depression, Epilepsy, Obesity), End User (Hospitals, ASCs, Clinics) & Region - Global Forecast to 2030

The global neuromodulation market is projected to reach USD 10.68 billion by 2030 from USD 6.81 billion in 2025, at a CAGR of 9.4% during the forecast period.

The neuromodulation market is expanding due to the rising prevalence of neurological disorders, the development of new neuromodulation technologies, and the increasing geriatric population, all of which contribute to market growth. Additionally, the high cost of neuromodulation procedures may limit the market growth.

“The hospitals & ambulatory surgery centers segment of the neuromodulation end user market is expected to hold the largest position during the forecast period.”

By end user, it is segmented into hospitals & ambulatory surgery centers, clinics & physiotherapy centers, and other end users. In 2024, hospitals & ambulatory surgery centers will hold the largest market share. The hospitals and ambulatory care segment dominates the neuromodulation market due to its ability to provide comprehensive, multidisciplinary care and access to advanced neuromodulation therapies. These settings are equipped with specialized surgical facilities, trained clinicians, and monitoring systems necessary for implantable and complex neuromodulation procedures. Hospitals and ambulatory centers also benefit from established reimbursement frameworks, making costly procedures more accessible to patients. Moreover, the increasing focus on chronic disease management, postoperative care, and patient follow-up is driving high procedure volumes in these settings, reinforcing their leadership in neuromodulation delivery solutions.

“The internal neuromodulation accounted for the largest market share in the neuromodulation market.”

The neuromodulation technology market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest share in the neuromodulation market in 2024. Internal neuromodulation has become the dominant approach in the market due to its sophisticated technology that facilitates targeted stimulation of specific neural pathways. This process is instrumental in the chronic management of conditions such as nociceptive pain, Parkinson's disease, and urinary or fecal incontinence. The implantable devices are characterized by features like rechargeable or long-lasting batteries, customizable stimulation protocols, closed-loop feedback mechanisms, and wireless connectivity. These capabilities enable real-time monitoring and tailored therapeutic adjustments to enhance patient outcomes. The technological advancements support compact device designs that minimize invasiveness, thereby improving patient comfort and adherence to treatment. Furthermore, ongoing innovation in materials science, electrode architecture, and software algorithms continues to improve the efficacy, safety, and longevity of these systems. As a result, internal neuromodulation is increasingly favored over non-invasive interventions in clinical practice.

“The Asia Pacific is the fastest-growing region of the neuromodulation market by region.”

The global neuromodulation market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing area in the neuromodulation market due to increasing health awareness, a rising rate of neurological and chronic pain disorders, and expanding healthcare infrastructure in countries like China, India, and Japan. The region is seeing greater adoption of advanced neuromodulation technologies, helped by better reimbursement policies and government efforts to improve access to medical devices. Additionally, a large patient population, higher disposable incomes, and increased investments from both global and local device manufacturers are fueling market growth. The push to establish specialized treatment centers and the gradual adoption of minimally invasive and implantable products further boost neuromodulation use in the region. Moreover, the rise in medical tourism in countries such as India, Thailand, and Singapore is increasing surgical volumes, which in turn raises the demand for post-operative care and neuromodulation.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1: 28%, Tier 2: 42%, and Tier 3: 30%
• By Designation: C Level: 30%, Director Level: 34%, and Others: 36%
• By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4%

Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 =

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the neuromodulation market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US).

Research Coverage

This report examines the neuromodulation market based on technology, stimulation type, application, end user, and country. It also analyzes factors such as drivers, restraints, opportunities, and challenges that influence market growth, along with details of the competitive landscape for market leaders. Additionally, the report studies micro markets according to their individual growth trends. It forecasts the revenue of market segments across five major regions and their respective countries.

Reasons to Buy the Report

The report will help both established and smaller firms to understand market trends, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies listed below to strengthen their market position.

This report provides insights into the following pointers:

• Analysis of key drivers (rising prevalence of neurological disorders and nerve injuries, rising geriatric population and subsequent growth in prevalence of neurological disorders, rising government support and funding for neurological disorders, increasing focus on development of advanced neuromodulation and neurostimulation technologies, increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices, and availability of reimbursements for neuromodulation devices), restraints (high cost of neuromodulation procedures, preference for drug therapies over neuromodulation products, and adverse effects and complications associated with neuromodulation devices), opportunities (large population and increasing healthcare expenditure in emerging economies, and widening application scope of neuromodulation), challenges (stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices, and shortage of trained professionals)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the neuromodulation market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the neuromodulation market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the neuromodulation market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

Show more